Skip to main content
Top
Published in: Abdominal Radiology 11/2021

01-11-2021 | Kidney Cancer | Kidneys, Ureters, Bladder, Retroperitoneum

MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma

Authors: Hiroaki Takahashi, Raghunandan Vikram, Rafael E. Jimenez, Candice W. Bolan, Akira Kawashima, Jose A. Karam, Naoki Takahashi

Published in: Abdominal Radiology | Issue 11/2021

Login to get access

Abstract

Purpose

To describe MR features of mucinous tubular spindle cell carcinoma (MTSCC) of the kidney that may help differentiate from clear cell renal cell carcinoma (ccRCC) and papillary RCC (pRCC).

Methods

15 MTSCCs were retrospectively evaluated by MR with T2-weighted image without fat suppression (n = 15) and dynamic contrast-enhanced (DCE), fat-suppressed T1-weighted GRE (n = 11). Size-matched ccRCC (n = 30) and pRCC (n = 30) were evaluated as control. T2 ratio was calculated as the signal intensity (SI) ratio of the lesion to the renal cortex on T2W images. Enhancement ratio (ER) was calculated as (SIpost − SIpre)/(SIpre), where SIpre (SIpost) is the SI of the entire lesion on each phase of DCE images. Early nodular enhancement was subjectively evaluated in MTSCC. T2 ratio and ER were compared using the Mann–Whitney U test with Bonferroni correction.

Results

The mean value of T2 ratio was highest in ccRCC (1.24), followed by MTSCC (1.02), and pRCC (0.84). Difference of T2 ratio was significant between ccRCC and pRCC (p < 0.001), but not between MTSCC and ccRCC (p = 0.4) or between MTSCC and pRCC (p = 0.2). The mean ER of MTSCC, ccRCC and pRCC were 1.33, 1.53 and 0.38 in corticomedullary phase (CMP), 1.60, 1.61 and 0.69 in nephrographic phase (NGP) and 1.79, 1.35 and 0.77 in excretory phase (EP), respectively. ERs were significantly different between MTSCC and pRCC in CMP (p = 0.01), NGP (p = 0.003), and EP (p = 0.002). Early nodular enhancement was observed in 4/11 MTSCC (36%), 17/30 ccRCC (57%), and 2/30 pRCC (7%).

Conclusions

MTSCC has distinct MR features that can help differentiate from ccRCC and pRCC. MTSCC enhances more avidly compared to pRCC and shows gradual progressive enhancement.
Literature
1.
go back to reference Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016;70(1):93-105.CrossRef Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016;70(1):93-105.CrossRef
2.
go back to reference Zhao M, He X-l, Teng X-d. Mucinous tubular and spindle cell renal cell carcinoma: a review of clinicopathologic aspects. Diagnostic Pathology. 2015;10(1). Zhao M, He X-l, Teng X-d. Mucinous tubular and spindle cell renal cell carcinoma: a review of clinicopathologic aspects. Diagnostic Pathology. 2015;10(1).
3.
go back to reference Algaba F, Akaza H, Lopez-Beltran A, Martignoni G, Moch H, Montironi R, et al. Current pathology keys of renal cell carcinoma. Eur Urol. 2011;60(4):634-43.CrossRef Algaba F, Akaza H, Lopez-Beltran A, Martignoni G, Moch H, Montironi R, et al. Current pathology keys of renal cell carcinoma. Eur Urol. 2011;60(4):634-43.CrossRef
4.
go back to reference Ged Y, Chen YB, Knezevic A, Donoghue MTA, Carlo MI, Lee CH, et al. Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. Clin Genitourin Cancer. 2019;17(4):268–74 e1. Ged Y, Chen YB, Knezevic A, Donoghue MTA, Carlo MI, Lee CH, et al. Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. Clin Genitourin Cancer. 2019;17(4):268–74 e1.
5.
go back to reference Cornelis F, Ambrosetti D, Rocher L, Derchi LE, Renard B, Puech P, et al. CT and MR imaging features of mucinous tubular and spindle cell carcinoma of the kidneys. A multi-institutional review. Eur Radiol. 2017;27(3):1087-95.CrossRef Cornelis F, Ambrosetti D, Rocher L, Derchi LE, Renard B, Puech P, et al. CT and MR imaging features of mucinous tubular and spindle cell carcinoma of the kidneys. A multi-institutional review. Eur Radiol. 2017;27(3):1087-95.CrossRef
6.
go back to reference Sahni VA, Hirsch MS, Sadow CA, Silverman SG. Mucinous tubular and spindle cell carcinoma of the kidney: imaging features. Cancer Imaging. 2012;12:66-71.CrossRef Sahni VA, Hirsch MS, Sadow CA, Silverman SG. Mucinous tubular and spindle cell carcinoma of the kidney: imaging features. Cancer Imaging. 2012;12:66-71.CrossRef
7.
go back to reference Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, et al. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int. 2015;116(1):85-92.CrossRef Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, et al. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int. 2015;116(1):85-92.CrossRef
8.
go back to reference Zhu Q, Zhu W, Wang Z, Wu J. Clinical and CT imaging features of mucinous tubular and spindle cell carcinoma. Chin Med J (Engl). 2014;127(7):1278-83.PubMed Zhu Q, Zhu W, Wang Z, Wu J. Clinical and CT imaging features of mucinous tubular and spindle cell carcinoma. Chin Med J (Engl). 2014;127(7):1278-83.PubMed
9.
go back to reference Wu J, Zhu Q, Zhu W, Chen W, Wang S. Comparative study of CT appearances in mucinous tubular and spindle cell carcinoma and collecting duct carcinoma of the kidney. Br J Radiol. 2015;88(1056):20140434.CrossRef Wu J, Zhu Q, Zhu W, Chen W, Wang S. Comparative study of CT appearances in mucinous tubular and spindle cell carcinoma and collecting duct carcinoma of the kidney. Br J Radiol. 2015;88(1056):20140434.CrossRef
10.
go back to reference Noon AP, Smith DJ, McAndrew P. Magnetic resonance imaging characterization of a mucinous tubular and spindle cell carcinoma of the kidney detected incidentally during an ectopic pregnancy. Urology. 2010;75(2):247-8.CrossRef Noon AP, Smith DJ, McAndrew P. Magnetic resonance imaging characterization of a mucinous tubular and spindle cell carcinoma of the kidney detected incidentally during an ectopic pregnancy. Urology. 2010;75(2):247-8.CrossRef
11.
go back to reference Tirumani SH, Assiri YI, Brimo F, Tsatoumas M, Reinhold C. Diffusion-weighted MR imaging of mucin-rich mucinous tubular and spindle cell carcinoma of the kidney: a case report. Clin Imaging. 2013;37(4):775-7.CrossRef Tirumani SH, Assiri YI, Brimo F, Tsatoumas M, Reinhold C. Diffusion-weighted MR imaging of mucin-rich mucinous tubular and spindle cell carcinoma of the kidney: a case report. Clin Imaging. 2013;37(4):775-7.CrossRef
12.
go back to reference Yasufuku T, Shigemura K, Fujisawa M. Mucinous tubular and spindle cell carcinoma. Int J Urol. 2009;16(4):425-6.CrossRef Yasufuku T, Shigemura K, Fujisawa M. Mucinous tubular and spindle cell carcinoma. Int J Urol. 2009;16(4):425-6.CrossRef
13.
go back to reference Roy C, El Ghali S, Buy X, Lindner V, Gangi A. Papillary renal cell carcinoma in allograft kidney. Eur Radiol. 2005;15(4):661-5.CrossRef Roy C, El Ghali S, Buy X, Lindner V, Gangi A. Papillary renal cell carcinoma in allograft kidney. Eur Radiol. 2005;15(4):661-5.CrossRef
14.
go back to reference Roy C, Sauer B, Lindner V, Lang H, Saussine C, Jacqmin D. MR Imaging of papillary renal neoplasms: potential application for characterization of small renal masses. Eur Radiol. 2007;17(1):193-200.CrossRef Roy C, Sauer B, Lindner V, Lang H, Saussine C, Jacqmin D. MR Imaging of papillary renal neoplasms: potential application for characterization of small renal masses. Eur Radiol. 2007;17(1):193-200.CrossRef
15.
go back to reference Wingen M, Alzen G, Gunther RW. MR imaging fails to detect bone marrow oedema in osteomyelitis: report of two cases. Pediatr Radiol. 1998;28(3):189-92.CrossRef Wingen M, Alzen G, Gunther RW. MR imaging fails to detect bone marrow oedema in osteomyelitis: report of two cases. Pediatr Radiol. 1998;28(3):189-92.CrossRef
16.
go back to reference Yoshimitsu K, Kakihara D, Irie H, Tajima T, Nishie A, Asayama Y, et al. Papillary renal carcinoma: diagnostic approach by chemical shift gradient-echo and echo-planar MR imaging. J Magn Reson Imaging. 2006;23(3):339-44.CrossRef Yoshimitsu K, Kakihara D, Irie H, Tajima T, Nishie A, Asayama Y, et al. Papillary renal carcinoma: diagnostic approach by chemical shift gradient-echo and echo-planar MR imaging. J Magn Reson Imaging. 2006;23(3):339-44.CrossRef
17.
go back to reference Woo S, Kim SY, Cho JY, Kim SH. Differentiation between papillary renal cell carcinoma and fat-poor angiomyolipoma: a preliminary study assessing detection of intratumoral hemorrhage with chemical shift MRI and T2*-weighted gradient echo. Acta Radiol. 2018;59(5):627-34.CrossRef Woo S, Kim SY, Cho JY, Kim SH. Differentiation between papillary renal cell carcinoma and fat-poor angiomyolipoma: a preliminary study assessing detection of intratumoral hemorrhage with chemical shift MRI and T2*-weighted gradient echo. Acta Radiol. 2018;59(5):627-34.CrossRef
18.
go back to reference Takahashi H, Kawashima A, Inoue A, Kozaka K, Potretzke TA, Froemming AT, et al. Hemosiderin deposition in papillary renal cell carcinoma and its potential to mask enhancement on MRI: analysis of 110 cases. Eur Radiol. 2020;30(11):6033-41.CrossRef Takahashi H, Kawashima A, Inoue A, Kozaka K, Potretzke TA, Froemming AT, et al. Hemosiderin deposition in papillary renal cell carcinoma and its potential to mask enhancement on MRI: analysis of 110 cases. Eur Radiol. 2020;30(11):6033-41.CrossRef
19.
go back to reference Jhaveri KS, Elmi A, Hosseini-Nik H, Hedgire S, Evans A, Jewett M, et al. Predictive Value of Chemical-Shift MRI in Distinguishing Clear Cell Renal Cell Carcinoma From Non-Clear Cell Renal Cell Carcinoma and Minimal-Fat Angiomyolipoma. AJR Am J Roentgenol. 2015;205(1):W79-86.CrossRef Jhaveri KS, Elmi A, Hosseini-Nik H, Hedgire S, Evans A, Jewett M, et al. Predictive Value of Chemical-Shift MRI in Distinguishing Clear Cell Renal Cell Carcinoma From Non-Clear Cell Renal Cell Carcinoma and Minimal-Fat Angiomyolipoma. AJR Am J Roentgenol. 2015;205(1):W79-86.CrossRef
20.
go back to reference Karlo CA, Donati OF, Burger IA, Zheng J, Moskowitz CS, Hricak H, et al. MR imaging of renal cortical tumours: qualitative and quantitative chemical shift imaging parameters. Eur Radiol. 2013;23(6):1738-44.CrossRef Karlo CA, Donati OF, Burger IA, Zheng J, Moskowitz CS, Hricak H, et al. MR imaging of renal cortical tumours: qualitative and quantitative chemical shift imaging parameters. Eur Radiol. 2013;23(6):1738-44.CrossRef
21.
go back to reference Yoshimitsu K, Honda H, Kuroiwa T, Irie H, Tajima T, Jimi M, et al. MR detection of cytoplasmic fat in clear cell renal cell carcinoma utilizing chemical shift gradient-echo imaging. J Magn Reson Imaging. 1999;9(4):579-85.CrossRef Yoshimitsu K, Honda H, Kuroiwa T, Irie H, Tajima T, Jimi M, et al. MR detection of cytoplasmic fat in clear cell renal cell carcinoma utilizing chemical shift gradient-echo imaging. J Magn Reson Imaging. 1999;9(4):579-85.CrossRef
22.
go back to reference Lim RS, Flood TA, McInnes MDF, Lavallee LT, Schieda N. Renal angiomyolipoma without visible fat: Can we make the diagnosis using CT and MRI? Eur Radiol. 2018;28(2):542-53.CrossRef Lim RS, Flood TA, McInnes MDF, Lavallee LT, Schieda N. Renal angiomyolipoma without visible fat: Can we make the diagnosis using CT and MRI? Eur Radiol. 2018;28(2):542-53.CrossRef
23.
go back to reference Sasiwimonphan K, Takahashi N, Leibovich BC, Carter RE, Atwell TD, Kawashima A. Small (<4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. Radiology. 2012;263(1):160-8.CrossRef Sasiwimonphan K, Takahashi N, Leibovich BC, Carter RE, Atwell TD, Kawashima A. Small (<4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. Radiology. 2012;263(1):160-8.CrossRef
24.
go back to reference Jeong CJ, Park BK, Park JJ, Kim CK. Unenhanced CT and MRI Parameters That Can Be Used to Reliably Predict Fat-Invisible Angiomyolipoma. AJR Am J Roentgenol. 2016;206(2):340-7.CrossRef Jeong CJ, Park BK, Park JJ, Kim CK. Unenhanced CT and MRI Parameters That Can Be Used to Reliably Predict Fat-Invisible Angiomyolipoma. AJR Am J Roentgenol. 2016;206(2):340-7.CrossRef
25.
go back to reference Galmiche C, Bernhard JC, Yacoub M, Ravaud A, Grenier N, Cornelis F. Is Multiparametric MRI Useful for Differentiating Oncocytomas From Chromophobe Renal Cell Carcinomas? AJR Am J Roentgenol. 2017;208(2):343-50.CrossRef Galmiche C, Bernhard JC, Yacoub M, Ravaud A, Grenier N, Cornelis F. Is Multiparametric MRI Useful for Differentiating Oncocytomas From Chromophobe Renal Cell Carcinomas? AJR Am J Roentgenol. 2017;208(2):343-50.CrossRef
Metadata
Title
MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma
Authors
Hiroaki Takahashi
Raghunandan Vikram
Rafael E. Jimenez
Candice W. Bolan
Akira Kawashima
Jose A. Karam
Naoki Takahashi
Publication date
01-11-2021
Publisher
Springer US
Published in
Abdominal Radiology / Issue 11/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-021-03227-0

Other articles of this Issue 11/2021

Abdominal Radiology 11/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.